



Press release
4 December, 2007

Kringle Pharma Successfully Raises 1.06 billion JPY to Accelerate the Development of HGF and NK4

Kringle Pharma, Inc. (Head office located in Toyonaka, Osaka; President & CEO, Kunio Iwatani; “KRINGLE”) announces that the company has successfully completed the financing round with a total amount of 1.06 billion Japanese Yen (approximately 10 million US dollars). The 15 companies in total that made an investment in KRINGLE include Nissei Capital Co., Ltd., as the lead investor, Nippon Venture Capital Co., Ltd., Nikko antfactory K.K. and Nippon Zenyaku Kogyo Co., Ltd.

From its establishment in 2001, KRINGLE has been keenly engaged in the clinical development of HGF (Hepatocyte Growth Factor), an intrinsic factor with an organotrophic role in the repair and regeneration of various tissues and organs, and NK4, an intermolecular fragment of HGF, a bi-functional and multi-target compound which functions as both an HGF-antagonist and an angiogenesis inhibitor for the treatment of various kinds of cancer. While KRINGLE has already completed the manufacture of the required volume of Good Manufacturing Practice (GMP) grade recombinant human HGF to conduct initial clinical studies (see Kringle Press Release dated June 12, 2007), invested capital in this round would be mostly placed to cover the costs to initiate clinical studies of recombinant human HGF for skin ulcer¹⁾ and acute renal failure (ARF)²⁾. Development activities targeting the application of recombinant human HGF for various indications, as well as preclinical studies of recombinant human NK4, will also be resourced by this financing.

“I am extremely proud that KRINGLE has succeeded in financing,” Kunio Iwatani stated. “In this round, KRINGLE was able to obtain financing, not only from the previous investors who have offered an additional investment, but also from new venture capital companies and business partners. With the capital resource secured by this financing, KRINGLE will accelerate its therapeutic development efforts of recombinant HGF and NK4 proteins to enrich KRINGLE’s product pipeline. We are aiming to form a strategic alliance with a major pharmaceutical company in the near future.”

- 1) Co-development in Sweden with Tripep AB (Head office located in Huddinge, Sweden; CEO, Jan Nilsson) (see Kringle Press Release dated February 21, 2007)
- 2) A phase I clinical trial to take place at The Rogosin Institute (Located in New York, US; Director, Dr. Albert Rubin) (see Kringle Press Release dated March 28, 2007)

About Kringle Pharma, Inc.

Kringle Pharma is a biopharmaceutical company spun-off from Osaka University. The company was established in 2001 to develop novel biopharmaceuticals based on HGF and NK4, both discovered by Professor Toshikazu Nakamura and Associate Professor Kunio Matsumoto at Osaka University (Dr. Matsumoto has been serving as a Professor at Kanazawa University since April 2007). HGF is considered as an intrinsic factor with an organotrophic role in the repair and regeneration of various tissues and organs, and is thought to have significant potential in becoming a regenerative medicine. NK4 is a molecule which functions as both an HGF-antagonist and an angiogenesis inhibitor that is induced by various growth factors



including HGF. NK4 is a bi-functional and multi-target compound developed by Kringle Pharma for the treatment of various kinds of cancer.

For more details on Kringle's technologies, please refer to the company's website at www.kringle-pharma.com/en/index.html

For more information, please contact:

Kiichi Adachi

EVP, Director of Business Development

Kringle Pharma, Inc.

Tel: +81-6-6831-3330

E-mail: adachi@kringle-pharma.com